ArticleNanomedicine : nanotechnology, biology, and medicine2015
Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 112 citations in OpenAlex.
- Functional synergistic effects of graphene nanoribbons and surfactant stabilizers on inhibition of growth of biofilm-forming and biofilm non-forming bacteria.Environmental science and pollution research international · 2026Article
- Comparative biodegradation of functionalized graphene oxide nanosheets by myeloperoxidase and neutrophil extracellular traps.Frontiers in bioengineering and biotechnology · 2026Article
- Graphene-Oxide Peptide-Containing Materials for Biomedical Applications.International journal of molecular sciences · 2024Review
- Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.Molecular neurobiology · 2024Review
- Application of Nanomaterial-Based Sonodynamic Therapy in Tumor Therapy.Pharmaceutics · 2024Review
- Graphene-Based Photodynamic Therapy and Overcoming Cancer Resistance Mechanisms: A Comprehensive Review.International journal of nanomedicine · 2024Review
- A Comprehensive Review of Inorganic Sonosensitizers for Sonodynamic Therapy.International journal of molecular sciences · 2023Review
- Review
- Potential Biomedical Limitations of Graphene Nanomaterials.International journal of nanomedicine · 2023Review
- The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases.Frontiers in neuroscience · 2023Review
- Progress and challenges of graphene and its congeners for biomedical applications.Journal of molecular liquids · 2022Article
- Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?Cancers · 2022Review
- Nanomedicine and graphene-based materials: advanced technologies for potential treatments of diseases in the developing nervous system.Pediatric research · 2022Review
- Nanoscale Drug Delivery Systems in Glioblastoma.Nanoscale research letters · 2022Review
- The Role of Graphene Oxide Nanocarriers in Treating Gliomas.Frontiers in oncology · 2022Review
- To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.Advanced drug delivery reviews · 2022Review
- Applications of Pristine and Functionalized Carbon Nanotubes, Graphene, and Graphene Nanoribbons in Biomedicine.Nanomaterials (Basel, Switzerland) · 2021Review
- Graphene Nanoribbons: Prospects of Application in Biomedicine and Toxicity.Nanomaterials (Basel, Switzerland) · 2021Review
- Use of graphene-based materials as carriers of bioactive agents.Asian journal of pharmaceutical sciences · 2021Review
- Sonosensitizer-Functionalized Graphene Nanoribbons for Adhesion Blocking and Sonodynamic Ablation of Ovarian Cancer Spheroids.Advanced healthcare materials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
We report use of PEG-DSPE coated oxidized graphene nanoribbons (O-GNR-PEG-DSPE) as agent for delivery of anti-tumor drug Lucanthone (Luc) into Glioblastoma Multiformae (GBM) cells targeting base excision repair enzyme APE-1 (Apurinic endonuclease-1). Lucanthone, an endonuclease inhibitor of APE-1, was loaded onto O-GNR-PEG-DSPEs using a simple non-covalent method. We found its uptake by GBM cell line U251 exceeding 67% and 60% in APE-1-overexpressing U251, post 24h. However, their uptake was ~38% and 29% by MCF-7 and rat glial progenitor cells (CG-4), respectively. TEM analysis of U251 showed large aggregates of O-GNR-PEG-DSPE in vesicles. Luc-O-GNR-PEG-DSPE was significantly toxic to U251 but showed little/no toxicity when exposed to MCF-7/CG-4 cells. This differential uptake effect can be exploited to use O-GNR-PEG-DSPEs as a vehicle for Luc delivery to GBM, while reducing nonspecific cytotoxicity to the surrounding healthy tissue. Cell death in U251 was necrotic, probably due to oxidative degradation of APE-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.